NR1H4 and hepatocellular carcinoma: Moreover, the combination of the FXR agonist GW4064 and an anti-PD-1 antibody achieved a tumor regression in a HCC syngeneic mouse model, implying the potential therapeutic value of an FXR agonist in HCC immunotherapy.